share_log

Morgan Stanley Maintains Equal-Weight on Prime Medicine, Lowers Price Target to $21

Benzinga Real-time News ·  Jan 24, 2023 09:23

Morgan Stanley analyst Matthew Harrison maintains Prime Medicine (NASDAQ:PRME) with a Equal-Weight and lowers the price target from $23 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment